TAO Synergies (TAOX) Depreciation & Amortization (CF) (2019 - 2026)
TAO Synergies' (TAOX) quarterly Depreciation & Amortization (CF) came in at $735.0 in Q2 2026, down 24.92% on a YoY basis from $979.0 in Q2 2025, and down 9.93% quarter-over-quarter from $816.0 in Q1 2026.
Powered by 
Analysis
TAO Synergies (TAOX) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $735.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Depreciation & Amortization (CF) fell 24.92% year-over-year to $735.0; the trailing twelve-month figure through Jun 2026 stood at $3156.0 (down 35.26% YoY), and the FY2025 full-year result was $3616.0, down 35.2% from the prior year.
- Depreciation & Amortization (CF) declined to $735.0 in Q2 2026 per TAOX's latest filing, from $816.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1724.0 in Q2 2023 and bottomed at $735.0 in Q2 2026.
- Historically, Depreciation & Amortization (CF) has averaged $1267.1 across 5 years, with a median of $1318.0 in 2022.
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) increased 28.13% in 2023, then slumped 52.46% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $1526.0 in 2022, then dropped by 20.71% to $1210.0 in 2023, then retreated by 2.89% to $1175.0 in 2024, then tumbled by 31.74% to $802.0 in 2025, then declined by 8.35% to $735.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $735.0, $816.0, and $802.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.40 Bn | 197.42 Bn | 7.24 Bn | 1.11 Bn |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.13 Bn | 124.28 Bn | 2.84 Bn | 56.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.53 Bn | 74.53 Bn | 3.93 Bn | 123.70 Mn |
| 5 | Argenx Se | 61.72 Bn | 56.54 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.67 Bn | 49.53 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.29 Bn | 30.00 Bn | 1.96 Bn | 236.10 Mn |
| 9 | Roivant Sciences | 30.03 Bn | 30.03 Bn | 1.16 Mn | 600,000.00 |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | 735.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 735.00 |
| Mar 31, 2026 | 816.00 |
| Dec 31, 2025 | 802.00 |
| Sep 30, 2025 | 803.00 |
| Jun 30, 2025 | 979.00 |
| Mar 31, 2025 | 1,032.00 |
| Dec 31, 2024 | 1,175.00 |
| Sep 30, 2024 | 1,689.00 |
| Jun 30, 2024 | 1,317.00 |
| Mar 31, 2024 | 1,399.00 |
| Dec 31, 2023 | 1,210.00 |
| Sep 30, 2023 | 1,723.00 |
| Jun 30, 2023 | 1,724.00 |
| Mar 31, 2023 | 1,690.00 |
| Dec 31, 2022 | 1,526.00 |
| Sep 30, 2022 | 1,491.00 |
| Jun 30, 2022 | 1,378.00 |
| Mar 31, 2022 | 1,319.00 |
| Dec 31, 2021 | 1,239.00 |
| Sep 30, 2021 | 1,240.00 |